Peptides Studied for Skin: What the Evidence Really Shows

Peptides are everywhere in skincare marketing. The evidence behind them is harder to find than the products. Many cosmetic peptide studies are small, run or funded by the company that makes the ingredient, or test a finished product containing several active ingredients at once. That last point matters: if a cream contains five actives, a good result can't be credited to any single one of them.

This guide covers the compounds most often discussed for skin. For each we give what it is, the strongest level of evidence we could find, and one or two findings sourced to PubMed. Where a study was company-run or tested a multi-ingredient product, we say so. We order compounds by strength of evidence, not by how well they might work, and nothing here is a recommendation.

How to read the evidence levels

• Human RCT: a randomized controlled trial with a placebo or vehicle (the same cream without the active). "Split-face" trials put the active on one side of the face and the vehicle on the other.
• Human, uncontrolled: people were treated, but there was no comparison group.
• In vitro / in silico: cell-culture tests or computer modelling only.

Summary table

Afamelanotide (Melanotan I)

What it is. A synthetic analogue of alpha-MSH, the hormone that stimulates skin pigment. See the Melanotan I page.

Strongest evidence: two multicenter RCTs, in a rare disease. In erythropoietic protoporphyria, a condition that makes sunlight acutely painful, 168 patients across US and European trials received afamelanotide implants or placebo. Pain-free time in direct sunlight rose (US median 69.4 vs 40.8 hours at 6 months), phototoxic reactions fell in the European study, and quality of life improved (Langendonk 2015). Funding came from Clinuvel Pharmaceuticals and others. This is medical research on a specific disorder, not evidence for cosmetic tanning.

Glutathione

What it is. A three-amino-acid antioxidant the body makes itself. See the L-glutathione page.

Strongest evidence: several small RCTs, pooled in a systematic review. The review found that topical 0.5% glutathione outperformed 0.1% and placebo, and that oral glutathione in five RCTs reduced a melanin index versus placebo. It found roughly equal numbers of studies at low and high risk of bias, and described topical and oral forms as moderately effective but "unsustainable." It advised against IV glutathione because of lack of efficacy and side effects (Sarkar 2025). In one trial of 46 people, combining topical and oral glutathione lowered the melanin index more than placebo (Wahab 2021).

Palmitoyl pentapeptide-4 (Matrixyl)

What it is. A synthetic five-amino-acid peptide (KTTKS) with a palmitoyl (fatty-acid) group attached, designed as a topical agent to stimulate collagen production. See the Matrixyl page.

Strongest evidence: RCTs, one industry-run. In a 12-week split-face trial of 93 women aged 35 to 55, a moisturizer with pal-KTTKS improved wrinkles and fine lines versus the same moisturizer without it (Robinson 2005). The authors worked for Procter & Gamble, a cosmetics maker. An 8-week trial in 21 Indonesian women, whose authors reported no conflicts of interest, found palmitoyl pentapeptide-4 cream performed better than both acetyl hexapeptide-3 (Argireline) cream and placebo, though the authors called it an initial study needing more participants (Aruan 2023).

Argireline (acetyl hexapeptide-8)

What it is. A six-amino-acid peptide (also listed as acetyl hexapeptide-3) designed to mimic part of SNAP-25, a protein nerves need to release signals, in the hope of relaxing expression lines. See the Argireline page.

Strongest evidence: one RCT. In 60 Chinese adults treated twice daily for 4 weeks, Argireline reduced skin-roughness measures around the eyes, with a 48.9% overall response on subjective scoring versus 0% for placebo (Wang 2013). The design paper reported that an emulsion containing 10% of the peptide reduced wrinkle depth by up to 30% after 30 days in healthy women, and that it inhibited neurotransmitter release in lab tests with far lower efficacy than botulinum toxin (Blanes-Mira 2002). That abstract does not give the number of volunteers or describe a control group.

It is often paired with GHK-Cu; see the GHK-Cu + Argireline stack. We found no trial of that combination.

OS-01

What it is. A peptide (also called Pep 14) studied for reducing senescent, or "aged," skin cells. See the OS-01 page.

Strongest evidence: a small company-run RCT. In a 12-week split-face study of 22 people, the OS-01 formulation reduced water loss through the skin and improved wrinkle and texture scores more than the vehicle (Zonari 2024). Most authors list OneSkin Inc. as their affiliation, and the company holds the article's copyright. The vehicle side also improved on some measures.

GHK-Cu

What it is. A natural three-amino-acid peptide bound to copper, found in human plasma. See the GHK-Cu page.

Strongest evidence: a small human RCT with a mostly null result. In 13 patients randomized to skin care with or without GHK-Cu after CO2 laser resurfacing, blinded evaluation found no difference in redness, wrinkles or skin quality; only patient satisfaction was higher (Miller 2006). A 2025 review noted "a surprising absence of clinical studies" of GHK-Cu and its palmitoylated form in anti-wrinkle use (Mortazavi 2025).

Cell data. GHK-Cu stimulated collagen production by fibroblasts at very low concentrations (Maquart 1988).

Decapeptide-12

What it is. A ten-amino-acid peptide that blocks tyrosinase, an enzyme needed to make melanin. See the decapeptide-12 page.

Strongest evidence: a 5-person pilot RCT. In a split-face pilot trial of five women with stubborn melasma, a proprietary tyrosinase-inhibiting oligopeptide sold as Lumixyl, applied at 0.01%, improved melasma over 16 weeks (Hantash 2009). Our decapeptide-12 page links this study, but the abstract itself does not use the name decapeptide-12. A later open-label study of 13 completers used decapeptide-12 as part of a system with a cleanser, glycolic-acid moisturizer and sunscreen, so its results cannot be credited to the peptide alone (Kassim 2012).

SNAP-8 (acetyl octapeptide-3)

What it is. An eight-amino-acid peptide, also listed as acetyl octapeptide-3. See the SNAP-8 page.

Strongest evidence: multi-ingredient products only. In 24 people, an overnight microneedle patch containing acetyl octapeptide-3 plus a vitamin C derivative and a third active improved eye wrinkles versus a patch made of hyaluronic acid alone (Shin 2024). A second patch study tested it alongside four other actives, with no control group described in the abstract (Avcil 2020). Both studies list company-employed authors (Raphas Co. appears on both), and neither can isolate SNAP-8's contribution.

Pentapeptide-18, Vialox and Syn-AKE

What they are. Short synthetic peptides used in cosmetic anti-ageing formulations. See Pentapeptide-18 (Leuphasyl), Vialox and Syn-AKE.

Strongest evidence: computer modelling and cell tests. Docking simulations predicted that Leuphasyl and Vialox bind enzymes involved in collagen breakdown and ageing, and neither harmed skin cells in culture (Akhan 2026). Similar modelling and antioxidant tests were reported for Syn-AKE (Gok 2024). We found no controlled human trial of any of the three on its own.

The bottom line

Skin peptide evidence is mostly small, short and often tied to the companies selling the ingredient. The strongest trials on this list concern a rare medical condition (afamelanotide) and skin lightening (glutathione), not wrinkles. For anti-ageing peptides, the best data come from a handful of split-face studies, and several popular ingredients have only been tested in blends or in cells.

Sources

• Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med, 2015. PMID 26132941
• Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol, 2025. PMID 39444151
• Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial. Int J Dermatol, 2021. PMID 33871071
• Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci, 2005. PMID 18492182
• Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol, 2023. PMID 36909866
• The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol, 2013. PMID 23417317
• A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci, 2002. PMID 18498523
• Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation. J Cosmet Dermatol, 2024. PMID 38400612
• Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006. PMID 16847171
• Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 2025. PMID 39963574
• Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett, 1988. PMID 3169264
• A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol, 2009. PMID 19663110
• Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. J Cosmet Laser Ther, 2012. PMID 22401652
• Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol, 2024. PMID 39082657
• Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol, 2020. PMID 31134751
• Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications. Chem Biodivers, 2026. PMID 42116636
• Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. J Biomol Struct Dyn, 2024. PMID 37349941

This article is for educational and research purposes only and is not medical advice.